San Diego, CA, Boston, MA, La Ciotat, France (PRWEB) May 23, 2016
CorTechs Labs, the leading medical software innovator providing solutions for quantitative brain volume analysis, and Olea Medical, a provider of advanced MR and CT imaging post-processing and visualization, are pleased to announce a partnership agreement to offer NeuroQuant® in Olea Sphere®, Olea Medical’s suite of innovative imaging applications.
The partnership will enrich physicians’ resources for accessing and quantifying neurodegeneration. NeuroQuant provides automatic, accurate and consistent measurements of brain structures through 3D T1 MRI images, allowing neurologists and radiologists to easily review, assess, quantify and monitor brain volume loss and changes over time, as compared to normative values.
NeuroQuant, the first FDA cleared, CE marked and Health Canada licensed software for measuring brain volumes and quantifying brain atrophy, is used in the assessment of neurodegeneration, such as Alzheimer’s disease, epilepsy, multiple sclerosis, as well as, brain volume changes caused by brain trauma.
Olea Sphere® is an image processing software package intended for picture archive, post-processing and communication. It helps standardize both viewing and analysis capabilities of functional and dynamic imaging datasets acquired with MRI and CT across vendors. It features innovative image viewing, analysis and processing of most complex MR sequences as well as longitudinal analysis of multiple time points. Olea Sphere® is compliant with the DICOM standard and Windows® or Linux® operating systems. Olea Sphere® runs on any standard off-the-shelf workstation or it can be used through thin deployment.
“We're very excited to partner with Olea Medical to provide our objective quantitative imaging solutions to neurologists and radiologists worldwide,” said Guri Stark, CorTechs Labs’ CEO. “We believe this collaboration will significantly benefit clinicians using Olea Sphere in their assessment of neurodegeneration and provide a beneficial insights for many brain disorders."
“We are always looking to provide our customers with enhanced and expanded imaging capabilities,” said Fayçal Djeridane, CEO, Olea Medical. “By adding NeuroQuant’s proven and validated solutions to our Olea Sphere offering, healthcare providers worldwide have access to innovative automated brain volume imaging technology, allowing them to deliver better patient care.”
For more information about using NeuroQuant in Olea Sphere, please visit CorTechs Labs at Booth 317 or Olea Medical at Booth 318 during the American Society of Neuroradiology (ASNR) 2016 Annual Meeting (May 23-25, Washington, DC).
About CorTechs Labs
CorTechs Labs develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. CorTechs Labs’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit http://www.cortechslabs.com for further information.
About Olea Medical
Olea Medical®, a provider of advanced MR and CT imaging post-processing, designs and markets a suite of innovative medical imaging applications, Olea Sphere®, significantly improving diagnostic process and follow-up assessment. The company has established a strong credibility, through the domestication of cutting-edge technology, and partnerships with leading institutions worldwide. With proprietary Bayesian algorithms and optimization methods applied to medical imaging, today Olea Medical® is the recognized leader in standardized, vendor-neutral, advanced MR quantitative and qualitative image post-processing. Covering both morphologic and functional imaging, Olea Medical® post-processing solutions bring complex mathematics into clinical practice for easy access to accurate and robust biomarkers for enhanced diagnostic confidence and response-to-treatment assessment. More information at http://www.olea-medical.com.